Pfizer executive exits leadership team
pharmafile | December 18, 2013 | News story | Sales and Marketing | Pfizer, Read, amy schulman
A leading big pharma figurehead who was to be instrumental in Pfizer’s future plans has stepped down unexpectedly.
Amy Schulman was one of the leadership team members selected by Pfizer chief executive Ian Read to spearhead its restructuring operations announced in July.
Schulman was the Group president of Pfizer’s Vaccines, Oncology and Consumer Healthcare business, and was also recently listed in Fortune’s 50 most powerful women in business.
A statement from Pfizer says: “Amy Schulman and Pfizer have agreed to separate,” and points out that she will not be assuming her named role and is also stepping down from the firm’s executive leadership team, including as General Counsel.
It added: “She will remain at the company for a transition period. We thank Amy for the past five years of hard work and many contributions, and we wish her well in her future endeavours.”
Stepping into her shoes in the same job from next year will be Albert Bourla, who begins his new role alongside Susan Silbermann who has been named president and general manager for its global vaccines business.
Read said: “Albert has 20 years of experience at Pfizer and has held senior global positions across a range of markets and disciplines within the company.”
Of Silbermann he added: “For the past year and a half Susan has led the vaccines portfolio within the Specialty Care business. Her experience in key global markets that represent potential growth opportunities will greatly benefit the Vaccines business.”
Doug Lankler who was to become General Counsel also from next year at Pfizer, and Rady Johnson who was to become Chief Compliance and Risk officer, both assume their new positions immediately it said.
Just how Schulman’s abrupt exit will impact upon Pfizer’s restructuring remains to be seen. As from January the company will be implementing Read’s strategy to make its business “more responsive to patient and shareholder needs”.
The group’s commercial operations will be split into three: two sections containing medicines in various therapy areas which are in patent, and the third made up of drugs which have lost, or will soon lose, market exclusivity.
Brett Wells
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
